Current Status and Prospects on PET Radiopharmaceuticals for Radiotherapy

DOI Web Site
  • Yoshimoto Mitsuyoshi
    Division of Functional Imaging, Exploratory Oncology Research and Clinical Trial Center (EPOC), National Cancer Center,

Bibliographic Information

Other Title
  • 放射線治療に関わるPET放射性薬剤の現状と展望
  • ホウシャセン チリョウ ニ カカワル PET ホウシャセイ ヤクザイ ノ ゲンジョウ ト テンボウ

Search this article

Abstract

18F-FDG is a most popular radiopharmaceutical for tumor diagnosis in the world. In addition, 11C-methionine, 18F-FLT and 11C-choline have been used to compensate for drawbacks of 18F-FDG. Now, novel radiopharmaceuticals are required to estimate or predict therapeutic efficacy because we have many strategies to treat tumors. Radiotherapy which damage DNA by producing free radicals is commonly used to treat various types of tumors. Hypoxia is closely associated with resistance to chemo- and/ or radiotherapy and is a common feature of solid tumors. Recently, understanding of tumor hypoxia in oncology has led to development of radiopharmaceuticals for hypoxia imaging. This review provides an overview of PET radiopharmaceuticals for hypoxia imaging and 18F-FBPA which is used for boron neutron capture therapy.

Journal

Keywords

Details 詳細情報について

Report a problem

Back to top